The approval makes methotrexate, currently, the only only oral liquid methotrexate on the market approved for both adult and pediatric indications.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

As the authors emphasized, “Expansion of these services will be essential to meet the needs of patients experiencing food allergy-related anxiety."

In all, 51.9% of patients entered with or achieved complete disease clearance at least once during the 48-week study.